How to Improve the Capturing of Antibody Fragments
contributed by Tosoh |
Introduction
Since 1986 and the first approval of therapeutic monoclonal antibody (mAb), the biopharmaceutical industry discovered a broad spectrum of diagnostic and therapeutic applications using antibody engineering. Some of the latest promising developments rely on antibody fragments. Antibody fragments are either separate functional subunits of antibodies or recombinant molecules, which, just like antibodies, are composed of immunoglobulin domains. The most popular fragments are Fab (Fragment antigen binding), scFv (single-chain Fragment variable), diabodies, and nanobodies[1].
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!